SEC Tracker
Get the app

PAVmed PAVM

PAVmed FY 2024: revenue $3.0M, up 20%; diluted EPS $0.50

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers PAVmed reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$3.0M+20% from $2.5M in FY 202310-K income statement, on EDGAR
  2. Net income$39.8MAgainst −$64.2M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS$0.50Against −$9.16 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$1.2M−94% from $19.6M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$33.6MAgainst −$52.0M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when PAVmed files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Intelligent Bio Solutions INBS public float $12M, Dec 31, 2025
  2. PetVivo Holdings PETV public float $12M, Jun 29, 2026
  3. Lyra Therapeutics LYRA public float $11M, Jun 30, 2025
  4. Nexgel NXGL public float $11M, Jun 30, 2025
  5. Envoy Medical COCH public float $13M, Dec 31, 2025